Oral Chronic Graft-Versus-Host Disease: Risk Factors and Markers of Disease Activity

Grant number: 28/2013 | Funding period: 2014 - 2014

Completed

Related publications (1)

Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients With Steroid-refractory Acute GRAFT-VS-HOST Disease (SR-AGVHD): 6-Month Follow-up From The Randomized, Phase 3 Reach2 Study

Mohamad Mohty, Claude-Eric Bulabois, Valentin Garcia-Gutierrez, David Ritchie, Sung-Soo Yoon, Valerie Coiteux, Yok-Lam Kwong, Dietger Niederwieser, Reuven Or, Gerard Socie, Nikolas von Bubnoff, Robert Zeiser, Judith Xu, Juliane Morando, Bruyere Mahuzier, Jeff Szer

2021-06-01

University of Melbourne Researchers

Michael McCullough

Jeffrey Szer